Preoperative smoking status and long-term survival after coronary artery bypass grafting: a competing risk analysis

Autores da FMUP
Participantes de fora da FMUP
- Abreu A.
- Máximo J.D.
Unidades de investigação
Abstract
OBJECTIVES: Patients with severe coronary artery disease who undergo coronary artery bypass grafting consistently demonstrate that continued smoking after surgery increases late mortality rates. Smoking may exert its harmful effects through the ongoing chronic process of atherosclerotic progression both in the grafts and the native system. However, it is not clear whether cardiac mortality is primary and solely responsible for the inferior late survival of current smokers. METHODS: In this retrospective analysis, we included all consecutive patients undergoing primary isolated coronary artery bypass surgery from 1 January 2000 to 30 September 2015 in an Academic Hospital in Northern Portugal. The predictive or independent variable was the patients' smoking history status, a categorical variable with 3 levels: non-smoker (the comparator), ex-smoker for >1 year (exposure 1) and current smoker (exposure 2). The primary end point was long-term all-cause mortality. Secondary outcomes were long-term cause-specific mortality (cardiovascular and noncardiovascular). We fitted overall and Fine and Gray subdistribution hazard models. RESULTS: We identified 5242 eligible patients. Follow-up was 99.7% complete (with 17 patients lost to follow-up). The median follow-up time was 12.79years (interquartile range, 9.51-16.60). Throughout the study, there were 2049 deaths (39.1%): 877 from cardiovascular causes (16.7%), 727 from noncardiovascular causes (13.9%) and 445 from unknown causes (8.5%). Ex-smokers had an identical long-term survival than non-smokers [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.88, 1.12; P¼0.899]. Conversely, current smokers had a 24% increase in late mortality risk (HR 1.24; 95% CI 1.07, 1.44; P¼0.004) as compared to non-smokers. While the current smoker status increased the relative incidence of noncardiac death by 61% (HR 1.61; 95% CI 1.27, 2.05, P<0.001), it did confer a 25% reduction in the relative incidence of cardiac death (HR 0.75; 95% CI 0.59, 0.97; P¼0.025). CONCLUSIONS: Whereas ex-smokers have an identical long-term survival to non-smokers, current smokers exhibit an increase in late all-cause mortality risk at the expense of an increased relative incidence of noncardiac death. By subtracting the inciting risk factor, smoking cessation reduces the relative incidence of cardiac death. © The Author(s) 2024.
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.
Dados da publicação
- ISSN/ISSNe:
- 1873-734X, 1010-7940
- Tipo:
- Article
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
European Journal of Cardio-thoracic Surgery Elsevier
Citações Recebidas na Scopus: 1
Documentos
- Não há documentos
Filiações
Keywords
- Aged; Coronary Artery Bypass; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Portugal; Preoperative Period; Retrospective Studies; Risk Assessment; Risk Factors; Smoking; acute heart infarction; adult; aged; all cause mortality; analysis of variance; anemia; aortic atherosclerosis; Article; body mass; cardiopulmonary bypass; cardiovascular disease; cardiovascular mortality; cerebrovascular accident; Charlson Comorbidity Index; chronic kidney failure; chronic obstructive lung disease; Cochran Armitage trend test; competing risk analysis; controlled study; coronary artery bypass graft; coronary artery disease; creatinine clearance; diabetes mellitus; female; Fine and Gray subdistribution hazard model; follow up; hazard ratio; health care planning; homoscedasticity; hospitalization; human; hyperlipidemia; hypertension; ICD-10; ICD-9-CM; incidence; independent variable; Kaplan Meier method; long term survival; longitudinal study; major clinical study; male; middle aged; mort
Financiamento
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
The Canadian CABG or PCI in Patients with Ischemic Cardiomyopathy Trial (STICH 3C) - NCT05427370
Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira
Ensaio Clínico Académico (STICH 3C) . Cornell University . 2023
Estudo do tratamento da doença valvular aórtica.
Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira
Estudo Observacional Académico (AORTA) . UniC . 2019
Eficácia da transposição de um pedículo adiposo pericárdico sobre o enfarte de miocárdio em pacientes (ensaio AGTP II)
Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira
Ensaio Clínico Académico (Ensaio AGTP II) . 2019
Aortic valve surgery with stented versus stentless bioprosthesis in patients with active infective endocarditis
Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira
Estudo Clínico Académico (Endocarditis) . 2023
Early Dual Antiplatelet Therapy versus Aspirin Monotherapy after Coronary Artery Bypass Surgery: survival and safety outcomes
Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira
Estudo Clínico Académico (Bypass) . 2020
Early and Midterm Outcomes following Aortic Valve Replacement with Mechanical versus Bioprosthetic Valves in Patients aged 50 to 70 Years
Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira
Estudo Clínico Académico (Aortic Valve Replacemen) . 2020
Efeito da terapêutica ß-bloqueadora pré-operatória após cirurgia de revascularização do miocárdio: sobrevida e complicações pós-operatórias
Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira
Estudo Clínico Académico . 2021
"Aortic valve surgery in patients with infective endocarditis: mid-term follow-up of patients treated with the St. Jude medical trifecta™ valve"
Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira
Estudo Clínico Académico . 2022
Long-term survival after coronary artery bypass grafting: the relevance of surgical procedures analysed by propensity score methods.
Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira
Estudo Clínico Académico (Arrtery bypass) . 2022
Abdominal Aortic Aneurysm - The Portuguese Case: Specificities and Consequences
Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira
Estudo Clínico Académico . 2022
New Insights into Epidemiology and Pathophysiology of Abdominal Aortic Aneurysms
Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira
Estudo Clínico Académico . 2021
Impacto clínico e hemodinâmico da substituição cirúrgica da válvula aórtica por biopróteses de última geração
Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira
Estudo Clínico Académico . 2020
Condicionamento isquémico cardíaco remoto como adjuvante da revascularização miocárdia na doença coronário aguda
Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira
Estudo Clínico Académico . 2020
Citar a publicação
Abreu A,Máximo JD,Leite A. Preoperative smoking status and long-term survival after coronary artery bypass grafting: a competing risk analysis. Eur. J. Cardio-Thorac. Surg. 2024. 65. (5):ezae183. IF:3,400. (1).